Oncology Institute (STLN) Stock Price, News & Analysis

Company Overview

Oncology Institute is a physician-led healthcare company focused on delivering specialized cancer care through an integrated oncology platform. Its services are designed to support patients throughout the cancer-care journey, including diagnosis, treatment planning, chemotherapy and other medical oncology services, supportive care, and ongoing disease management.

The company’s business model emphasizes value-based oncology care, with care coordination and clinical programs intended to improve outcomes while managing the overall cost of treatment. Its platform may also include access to clinical trials, specialty pharmacy services, genetic testing, and other resources that support personalized cancer treatment.

Founded in 2017, Oncology Institute has built a network-based practice serving patients through community oncology locations and affiliated providers, primarily in the United States. The company’s operations have historically been concentrated in states including California, Nevada, and Florida. Publicly available information about its current leadership and geographic footprint may change over time.

Key Stats

• Today's Range: $5.87 to $5.98
• 50-Day Range: N/A
• 52-Week Range: $2.32 to $7.05
• Volume: 359,030 shs
• Average Volume: 1.84 million shs
• Market Capitalization: $586.12 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.50
• Consensus Rating: Moderate Buy

Oncology Institute Stock Analysis - MarketRank™

Oncology Institute scored higher than 62% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Oncology Institute has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on no strong buy ratings, 4 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Oncology Institute has a consensus price target of $8.50, representing about 43.3% upside from its current price of $5.93.

Amount of Analyst Coverage

Oncology Institute has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.7 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Oncology Institute are expected to grow in the coming year, from ($0.21) to ($0.05) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Oncology Institute is -19.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

7.29% of the float of Oncology Institute has been sold short.

Short Interest Ratio / Days to Cover

Oncology Institute has a short interest ratio ("days to cover") of 3.51, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Oncology Institute has recently decreased by 3.78%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Oncology Institute does not currently pay a dividend.

Dividend Growth

Oncology Institute does not have a long track record of dividend growth.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: N/A

Search Interest

6 people have searched for STLN on MarketBeat in the last 30 days.

MarketBeat Follows

4 people have added Oncology Institute to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days.

Company Ownership

• Score: 2.0 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Oncology Institute insiders have sold 407.21% more of their company's stock than they have bought. Specifically, they have bought $408,450.00 in company stock and sold $2,071,699.00 in company stock.

Percentage Held by Insiders

4.40% of the stock of Oncology Institute is held by insiders.

Percentage Held by Institutions

36.86% of the stock of Oncology Institute is held by institutions.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 9/04/2026
• Wells Fargo 21st Annual Healthcare Conference: 9/08/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: NASDAQ:STLN
• Previous Symbol: NASDAQ:TOI
• CIK: 1799191
• Web: theoncologyinstitute.com
• Phone: (562) 735-3226
• Fax: N/A
• Employees: 660
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Oncology Institute: $8.50
• High Price Target: $10.00
• Low Price Target: $7.00
• Potential Upside/Downside: +42.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.60
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.30)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$60.61 million
• Net Margins: -6.18%
• Pretax Margin: -6.18%
• Return on Equity: N/A
• Return on Assets: -21.51%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.36
• Quick Ratio: 1.15

Sales & Book Value

• Annual Sales: $502.73 million
• Price / Sales: 1.17
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.25) per share
• Price / Book: -23.88

Miscellaneous

• Outstanding Shares: 98,840,000
• Free Float: 94,490,000
• Market Cap: $589.98 million
• Optionable: N/A
• Beta: 0.41